The following represents disclosure information provided by authors of this abstract. The ASCO Scientific Program Committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered self-held and compensated unless otherwise noted. Employment/Leadership relationships are considered compensated employment unless otherwise noted. L = Leadership, U = Uncompensated, I = Immediate Family Member, B = Both Myself and Immediate Family Member, Inst = My Institution
Robustness of circadian rest-activity rhythm for predicting efficacy of intravenous cetuximab (Cet) and hepatic artery infusion (HAI) of chronomodulated irinotecan, 5-fluorouracil and oxaliplatin (Chrono-Optiliv) for liver metastases from colorectal cancer (LM-CRC) (Optiliv translational study, NCT00852228).
Abdoulaye Karaboué
No relevant relationships to disclose
Pasquale F. Innominato
No relevant relationships to disclose
Mohamed Bouchahda
No relevant relationships to disclose
Magali Mocquery
No relevant relationships to disclose
Rachel Bossevot
No relevant relationships to disclose
Virginie Plessis
No relevant relationships to disclose
Davina Bouchoucha
No relevant relationships to disclose
Rene Adam
No relevant relationships to disclose
Francis Levi
No relevant relationships to disclose